Search results for "Therapeutic monitoring"

showing 5 items of 5 documents

Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report.

2016

This study was directed to assess the clinical impact of the circulating cathepsin L, cystatin C, activin A, and follistatin in breast cancer patients. The serum concentrations of these molecules were determined by immunoenzymatic assays, and their association with some clinico-pathological parameters of breast cancer progression was evaluated. Our results identified cystatin C and activin A as predictive markers for the presence of breast cancer and bone metastasis, respectively. Therefore, these proteins may have a clinical role as circulating biomarkers in the diagnosis and therapeutic monitoring of breast cancer patients.

0301 basic medicineCancer ResearchFollistatinCathepsin LBone NeoplasmsBreast NeoplasmsActivinCathepsin L03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerPreliminary reportmedicineBiomarkers TumorHumansbone metastasiCystatin CNeoplasm Metastasisskin and connective tissue diseasesAgedNeoplasm Stagingbiologybusiness.industryBone metastasisGeneral MedicineMiddle Agedmedicine.diseaseTherapeutic monitoringActivinsActivin a030104 developmental biologyOncologyCystatin CROC Curvetumor markers030220 oncology & carcinogenesisSettore BIO/14 - Farmacologiabiology.proteinCancer researchDisease ProgressionbiomarkerOsteoporosisFemaleNeoplasm Gradingbusinesshormones hormone substitutes and hormone antagonistsFollistatinCancer investigation
researchProduct

Vacuolated PAS-Positive Lymphocytes on Blood Smear: An Easy Screening Tool and a Possible Biomarker for Monitoring Therapeutic Responses in Late Onse…

2018

Background: Primary aim was to investigate the diagnostic value of PAS-positive vacuolated lymphocytes on blood smear in Late Onset Pompe Disease (LOPD) patients and, secondly, to evaluate its potential utility in monitoring treatment effects.Methods: We examined blood smear of 26 LOPD patients. We evaluated 10 treated and 16 untreated LOPD patients. Among the latter group, 7 patients later initiated ERT and were tested again 6 months after start. Blood smear was also sampled from 82 controls and 19 patients with other muscle glycogenoses (MGSDs). PAS staining was used to evaluate: (1) presence of lymphocytes with glycogen-filled vacuoles, (2) quantification of vacuolated lymphocytes.Result…

0301 basic medicinemedicine.medical_specialtytherapeutic monitoringBlood smear; LOPD screening test; PAS-positive lymphocytes; Pompe disease; Therapeutic monitoring; Neurology; Neurology (clinical)Late onsetPeriodic acid–Schiff stainDiseasePAS-positive lymphocytesGastroenterologylcsh:RC346-429Vacuolated Lymphocytes03 medical and health sciences0302 clinical medicineInternal medicineBlood smear; LOPD screening test; PAS-positive lymphocytes; Pompe disease; Therapeutic monitoringmedicineScreening toolLOPD screening testlcsh:Neurology. Diseases of the nervous systemOriginal Researchbusiness.industryPompe diseasePredictive value030104 developmental biologyBlood smearNeurologyblood smearBiomarker (medicine)Neurology (clinical)business030217 neurology & neurosurgeryFrontiers in neurology
researchProduct

Atherosclerosis and Cerebral Ischemic Attacks: Intakes of Cerebrography With Xenon133 Inhaled and Platelet Tests in the Diagnosis, Clinical and Thera…

1984

A study of patients to develop the significance of the role of the blood plate lets in the recurrence of transient cerebral ischemic attacks in patients with cerebral atheromatous, develop the effectiveness of dipyridamole in the prophy lactic therapeutic regimen. In the group treated with dipyridamole, a 76.3% clinical improvement was recorded (mean increases of 11.2 ml/min. and 11.4 ml/min. of the cerebral hemispheric flows), 15.8% of cases stabilized (mean increases of 1.7 ml/min. and 1.2 ml/min.) and 7.9% failures (mean decreases of 10.4 ml/min. and 14.3 ml/min.) of these same flows. The cerebrography with xenon 133 inhaled as well as the platelet tests used, constitute unfailing means…

AdultMalemedicine.medical_specialtyPlatelet AggregationArteriosclerosismedicine.medical_treatmentVasodilation030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansPlatelet030212 general & internal medicineAgedAerosolsChemotherapyTherapeutic regimenbusiness.industryDipyridamoleArteriosclerosisMiddle Agedmedicine.diseaseSurgeryTherapeutic monitoringDipyridamoleIschemic Attack TransientCardiovascular agentCardiologyFemaleCardiology and Cardiovascular MedicinebusinessXenon Radioisotopesmedicine.drugAngiology
researchProduct

Extra Corporeal Oxygenation & Ozonation, EBOO & AQUAPHERESIS method of Ozone Therapy, Clinical Application in Chronic Diseases [abstract]

2018

Introduction: The top 10 causes of death around the world are usually ranked with heart diseases, cancers, drugs/medication/iatrogenic chemicals, strokes etc. These are totally detectable, predictable, avoidable, preventable because it is classified as non-communicable diseases. Acute diseases are denoted by acute inflammation which has intensive cell-cell communications, resulting intensive repair rebuilding rehabilitation and it is life extending. Often it is self defensive and we over come it. The real culprit for chronic diseases is chronic inflammations, denoted by constant & silent, undetectable & insensible lost of cell-cell signaling, basement membrane disease, tight junctio…

Aquapheresismedicine.medical_specialtyEBOObusiness.industrymedicine.medical_treatmentAcute diseasesDiseaseOxygenationOzone therapy:CIENCIAS MÉDICAS [UNESCO]Therapeutic monitoringBlood exposureUNESCO::CIENCIAS MÉDICASmedicineIntensive care medicinebusiness
researchProduct

Actionable Molecular Targets in Cancer Liquid Biopsy

2017

The possibility to detect nucleic acid sequences in the bloodstream deriving from an underlying tumor process has disclosed a unique opportunity in medical oncology. Whether the nucleic acid material is leaked in the blood at any step of cancer development (circulating tumor DNA or ctDNA) or it is obtained from isolated circulating tumor cells (CTCs), the detection and analysis of the meaningful sequence defects harbored in instrumental molecular targets (which we call liquid biopsy) constitutes an invaluable tool toward leading the current oncology practice toward a less invasive and fully personalized diagnostic-therapeutic workflow. In spite of the current technical limitations that liqu…

Circulating tumor cellWorkflowTest materialCancer genomemedicineMolecular targetsCancerComputational biologyLiquid biopsymedicine.diseaseTherapeutic monitoring
researchProduct